Fortress Biotech (FBIO) 10-Q 9 Nov 15 2015 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 09, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Entity Registrant Name	Fortress Biotech, Inc.
Entity Central Index Key	1,429,260
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	FBIO
Entity Common Stock, Shares Outstanding		47,133,715

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$ 25,563	$ 49,759
Marketable securities, at fair value (Note 3)	39,951	20,002
Prepaid expenses and other current assets	1,096	702
Total current assets	66,610	70,463
Property and equipment, net	129	52
Restricted cash	14,586	14,586
Long-term investments, at fair value (Note 11)	4,095	4,160
Intangible asset - license (Note 6)	1,250	0
Other assets	194	64
Total assets	86,864	89,325
Current liabilities
Accounts payable	1,287	366
Interest payable	26	28
Accrued expenses	7,137	3,683
Total current liabilities	8,450	4,077
Notes payable, long-term, net (net of debt discount of $718 and $6 at September 30, 2015 and December 31, 2014, respectively)	23,291	14,003
Other long-term liabilities	202	722
Total liabilities	$ 31,943	$ 18,802
Commitments and contingencies
Stockholders' equity
Common Stock, $.001 par value, 100,000,000 shares authorized, 47,133,715 and 46,494,034 shares issued and outstanding as of September 30, 2015 and December 31, 2014, respectively	$ 47	$ 46
Additional paid-in-capital	231,684	212,205
Accumulated deficit	(178,120)	(141,728)
Total stockholders' equity attributed to the Company	53,611	70,523
Non-controlling interests (Note 5)	1,310	0
Total stockholders' equity	54,921	70,523
Total liabilities and stockholders' equity	86,864	89,325
Series C Convertible Preferred Stock [Member]
Stockholders' equity
Convertible Preferred stock, $.001 par value, 129,767 Series C shares authorized, 0 shares issued and outstanding as of September 30, 2015 and December 31, 2014, respectively	$ 0	$ 0

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Debt Instrument, Unamortized Discount	$ 718	$ 6
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	47,133,715	46,494,034
Common Stock, shares outstanding	47,133,715	46,494,034
Series C Convertible Preferred Stock [Member]
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	129,767	129,767
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue - from a related party	$ 25	$ 0	$ 525	$ 0
Operating expenses
Research and development	9,073	1,609	13,172	8,473
Research and development - licenses acquired	1,895	0	10,882	0
General and administrative	7,129	2,737	14,376	7,218
Total operating expenses	18,097	4,346	38,430	15,691
Loss from operations	(18,072)	(4,346)	(37,905)	(15,691)
Other income (expenses)
Interest income	39	168	195	517
Interest expense	(350)	(121)	(1,033)	(1,206)
Change in fair value of investments	(1,472)	(293)	(65)	(293)
Total other income (expenses)	(1,783)	(246)	(903)	(982)
Net loss	(19,855)	(4,592)	(38,808)	(16,673)
Less: net loss attributable to non-controlling interest	1,694	0	2,416	0
Net loss attributable to common stockholders	$ (18,161)	$ (4,592)	$ (36,392)	$ (16,673)
Basic and diluted net loss per common share	$ (0.46)	$ (0.13)	$ (0.93)	$ (0.46)
Weighted average common shares outstanding - basic and diluted	39,412,056	36,024,810	39,038,522	35,977,355

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash Flows from Operating Activities:
Net Loss	$ (38,808)	$ (16,673)
Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization	17	17
Noncash interest expense	167	555
Amortization of debt discount	143	0
Stock-based compensation expense	11,896	4,082
Change in fair value of investment	65	293
Asset impairment loss	0	723
Unrealized gain on marketable securities	(11)	0
Increase (decrease) in cash resulting from changes in assets and liabilities:
Prepaid expenses and other current assets	(394)	(31)
Accounts payable and accrued expenses	4,375	(1,366)
Interest payable	(2)	(84)
End of term fee associated with Hercules Note	0	(398)
Other long term liabilities	(687)	75
Net cash used in Operating Activities	(23,239)	(12,807)
Cash Flows from Investing Activities:
Purchase of marketable securities, at fair value	(19,938)	0
Purchase of short- term investment	0	(345)
Purchase of long-term investment	0	(250)
Purchase of property and equipment	(94)	0
Purchase of license	(1,250)	0
Payment to related parties - CB Pharma Acquisition Corp	(130)	0
Net cash used in Investing Activities	(21,412)	(595)
Cash Flows from Financing Activities:
Payment of Hercules Note	0	(13,655)
Proceeds from issuance of common stock	0	606
Proceeds from the exercise of stock options	216	0
Proceeds from issuance of common stock under ESPP	26	0
Proceeds from subsidiary's public offering	12,575	0
Payment of costs related to subsidiary's public offering	(1,507)	0
Payment of costs related to the issuance of common stock	0	(32)
Proceeds from IDB note	0	14,009
Payment of debt issue costs associated with IDB Note	0	(9)
Proceeds from NSC note	10,000	0
Payment of debt issue costs associated with NSC Note	(855)	0
Transfer of restricted cash	0	(15,446)
Net cash provided by (used in) Financing Activities	20,455	(14,527)
Net decrease in cash and cash equivalents	(24,196)	(27,929)
Cash and cash equivalents at beginning of period	49,759	99,521
Cash and cash equivalents at end of period	25,563	71,592
Supplemental disclosure of cash flow information:
Cash paid for interest	80	614
Supplemental disclosure of non-cash financing and investing activities:
Issuance of restricted stock	$ 1	$ 4

Organization and Description of

Organization and Description of Business	9 Months Ended
	Sep. 30, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Description of Business	Fortress Biotech, Inc., formerly Coronado Biosciences, Inc. (“Fortress” or “the Company”), is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. On April 27, 2015, the Company changed its name from Coronado Biosciences, Inc. to Fortress Biotech, Inc. Fortress plans to develop and commercialize products both within Fortress and within subsidiary companies, also known as Fortress Companies. In addition to its internal development programs, the Company will leverage its biopharmaceutical business expertise and drug development capabilities to help the Fortress Companies achieve their goals. Additionally, the Company will provide funding and management services to each of the Fortress Companies and, from time to time, the Company and the Fortress Companies will seek licensing, partnerships, joint ventures and/or public and private financings to accelerate and provide additional funding to support their research and development programs. As of September 30, 2015, the Company has several consolidated Fortress Companies, which contain product licenses, including Avenue Therapeutics, Inc. (“Avenue”), Journey Medical Corporation (“JMC”), Coronado SO Co. (“Coronado SO”), Checkpoint Therapeutics, Inc. (“Checkpoint”), Mustang Bio, Inc. (“Mustang”), Helocyte, Inc. (“Helocyte”), formerly DiaVax Biosciences, Inc. (“DiaVax”), Escala Therapeutics, Inc. (“Escala”), formerly Altamira Biosciences, Inc. (“Altamira”), and other consolidated Fortress subsidiaries which have minimal activity, including Innmune Limited, CB Securities Corporation (holds treasury bills classified as marketable securities), and Cyprium Therapeutics, Inc. Recent Events Fortress Companies On September 30, 2015, a subsidiary of Fortress closed the first tranche of a confidential private placement offering raising approximately $12.6 million. Expenses associated with this tranche approximated $1.5 million. Checkpoint Therapeutics, Inc. In March 2015, the Company formed Checkpoint, an immuno-oncology focused company. To date, Checkpoint has licensed a portfolio of fully human immuno-oncology targeted antibodies generated in the laboratory of Dr. Wayne Marasco, MD, PhD, a professor in the Department of Cancer Immunology and AIDS at the Dana-Farber Cancer Institute (“Dana-Farber”). The portfolio includes antibodies targeting Programmed-death Ligand 1 (“PD-L1”), glucocorticoid-induced TNFR-related protein (“GITR”) and carbonic anhydrase 9 (“CAIX”). Checkpoint plans to develop these novel immuno-oncology and checkpoint inhibitor antibodies on their own and in combination with each other, as data suggests that combinations of these targets can work synergistically together. The Company expects clinical trials to start in the second half of 2016. Additionally, effective March 2015, Fortress assigned its license from NeuPharma, Inc. (“NeuPharma”) for a small molecule inhibitor of epidermal growth factor receptor (“EGFR”) mutations to Checkpoint. Clinical trials for this program are expected to start in the first half of 2016 (see Note 4). In connection with the license agreement with Dana-Farber, Checkpoint entered into a collaboration agreement with TG Therapeutics, Inc. (“TGTX”) to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. Further, in connection with the NeuPharma license, Checkpoint entered into an option agreement with TGTX for a global collaboration in connection with the future development of the certain compounds licensed. Michael Weiss, the Company’s Executive Vice Chairman, Strategic Development is also Co-Portfolio Manager and a Partner of Opus Point Partners Management, LLC (“OPPM”) with Dr. Lindsay Rosenwald, the Company’s Chairman and Chief Executive Officer. Further, Mr. Weiss is the Executive Chairman, Interim President and Chief Executive Officer and a stockholder of TGTX. Checkpoint retains the right to develop and commercialize these antibodies in the field of solid tumors. Both programs are currently in pre-clinical development. On September 15, 2015, Checkpoint entered into a Sponsored Research Agreement with NeuPharma to identify additional inhibitors with differing profiles from the licensed products. Under the terms of the agreement, Checkpoint will pay NeuPharma for specific sponsored research projects. Mustang Bio, Inc. In March 2015, the Company formed Mustang to develop immunotherapies based on Chimeric Antigen Receptor Technology (“CAR-T”) and Mustang entered into a license agreement with the City of Hope (“COH”) to acquire such technology. In connection with the license agreement, Mustang also entered into a Sponsored Research Agreement with the COH in which Mustang will fund continued research at the COH of CAR-T (see Note 4). Coronado SO Co. In February 2015, Coronado SO entered into an exclusive license agreement with a third party for a topical product used in the treatment of Hand-Foot Syndrome, a common painful side effect of chemotherapeutics (see Note 4). Journey Medical Corporation In March 2015, JMC, the Company’s dermatology focused subsidiary, entered into a license and supply agreement to acquire rights to distribute a dermatological product for the treatment of acne (see Note 6). Avenue Therapeutics, Inc. In February 2015, the Company purchased an exclusive license to an intravenous (“IV”) formulation of Tramadol for the U.S. market from Revogenex Ireland Limited (“Revogenex”). Tramadol is a centrally acting synthetic opioid analgesic for moderate to moderately severe pain and is available as immediate release or extended-release tablets in the United States. The Company intends to transfer the IV Tramadol license and rights to Avenue during the fourth quarter of 2015 in order to establish a Fortress Company focused on the acquisition, licensing, development and commercialization of products principally for use in the acute/intensive care hospital setting (see Note 4). Helocyte, Inc. Helocyte, formerly DiaVax, was formed to develop novel immunotherapies for the prevention and treatment of cytomegalovirus (“CMV”), a common virus that affects people of all ages. On April 2, 2015, Helocyte entered into an agreement with the COH to secure exclusive worldwide rights for two T-cell immunotherapeutic vaccines for controlling CMV in allogeneic hematopoietic stem cell transplant (“HSCT”) and solid organ transplant (“SOT”) recipients. Known as Triplex and PepVax, the programs are expected to enter Phase II clinical studies later this year and are supported by grants paid and payable to the COH from the National Cancer Institute. In connection with the licensing of Triplex and PepVax, Helocyte further entered into an option agreement with the COH (the “Option”) for exclusive worldwide rights to Pentamer, a universal immunotherapeutic vaccine being developed for the prevention of CMV transmission in utero, and exercised this Option on April 28, 2015 (see Note 4). Escala Therapeutics, Inc. On July 16, 2015, Escala, formerly Altamira, acquired from New Zealand Pharmaceuticals Limited (“NZP”) a license from the National Institutes of Health (“NIH”) and Cooperative Research and Development Agreements (“CRADAs”) for the development of oral N-acetyl-D-mannosamine (“ManNAc”), a key compound in the sialic biosynthetic pathway for the treatment of hyposialylation disorders, including GNE myopathy and various forms of nephropathy (see Note 4).

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on March 16, 2015 and amended on April 30, 2015, from which the Company derived the balance sheet data at December 31, 2014. The Company’s unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries: Innmune Limited, Coronado SO, Cyprium Therapeutics, Inc., Escala, JMC, CB Securities Corporation, Avenue, Checkpoint, Mustang and Helocyte. All intercompany balances and transactions have been eliminated. The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. The Company reclassified debt issuance costs from other assets to notes payable, long-term, net on the unaudited condensed consolidated balance sheets for all periods presented pursuant to the early adoption of Accounting Standards Update (“ASU”) No. 2015-03 - Simplifying the Presentation of Debt Issuance Costs The Company records cash held in trust or pledged to secure certain debt obligations as restricted cash. As of September 30, 2015, the Company has $ 14.6 14.0 0.6 The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories: Level 1 : Quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Certain of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities. The carrying value of the amount owed to Ovamed GmbH (“Ovamed”) upon the acquisition of certain manufacturing rights in December 2012 under the amendment to the sublicense agreement with Ovamed included in current liabilities in the September 30, 2015 unaudited condensed consolidated balance sheet and both current liabilities and long-term liabilities in the December 31, 2014 consolidated balance sheet, has been recorded at its net present value, which approximates its fair value (see Note 10). The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. During the nine month period ended September 30, 2014, in relation to the abandonment of its lease in Woburn, MA, the Company recorded an impairment loss of $ 0.4 The Company elected the fair value option for its investment in a third-party company developing a laser device to treat migraine headaches, and its investment in CB Pharma Acquisition Corp. (“CB Pharma”). As of September 30, 2015, the fair value of these investments approximate $ 4.1 While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The decision to elect the fair value option, which is irrevocable once elected, is determined on an instrument by instrument basis and applied to an entire instrument. The net gains or losses, if any, on an investment for which the fair value option has been elected, are recognized as a change in fair value of investments in the unaudited condensed consolidated statements of operations. Reimbursement Arrangements The Company, via the collaboration agreement between Checkpoint and TGTX, is reimbursed by TGTX for its share of the cost of the license and future milestone payments that are payable to Dana-Farber pursuant to the license agreement (for further discussion, see Note 1). The gross amount of these reimbursed costs are reported as revenue in the accompanying unaudited condensed consolidated statements of operations. The Company acts as a principal (as the Company is responsible for designing the future clinical development pathway), bears credit risk and may perform part of the services required in the transactions. Consistent with ASC 605-45, Revenue Recognition – Principal Agent Considerations, Collaborative Arrangements The Company recognizes revenue for the performance of services or the shipment of products when each of the following four criteria is met: (i) persuasive evidence of an arrangement exists; (ii) products are delivered or as services are rendered; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured. The Company follows ASC 605-25, Revenue Recognition – Multiple-Element Arrangements Collaborative Arrangements ASC 605-25 provides guidance relating to the separability of deliverables included in an arrangement into different units of accounting and the allocation of arrangement consideration to the units of accounting. The evaluation of multiple-element arrangements requires management to make judgments about (i) the identification of deliverables, (ii) whether such deliverables are separable from the other aspects of the contractual relationship, (iii) the estimated selling price of each deliverable, and (iv) the expected period of performance for each deliverable. To determine the units of accounting under a multiple-element arrangement, management evaluates certain separation criteria, including whether the deliverables have stand-alone value, based on the relevant facts and circumstances for each arrangement. Management then estimates the selling price for each unit of accounting and allocates the arrangement consideration to each unit utilizing the relative selling price method. The allocated consideration for each unit of accounting is recognized over the related obligation period in accordance with the applicable revenue recognition criteria. If there are deliverables in an arrangement that are not separable from other aspects of the contractual relationship, they are treated as a combined unit of accounting, with the allocated revenue for the combined unit recognized in a manner consistent with the revenue recognition applicable to the final deliverable in the combined unit. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as deferred revenue in the condensed consolidated balance sheets and recognized as revenue in the condensed consolidated statements of operations when the related revenue recognition criteria are met. See Note 4 for a description of the collaborative arrangements. The Company records the costs of acquired product license rights as intangible asset licenses in the condensed consolidated balance sheets. Upon commencement of product sales, license rights will be amortized over the expected life of the product into product expense in the condensed consolidated statements of operations. As of September 30, 2015, product sales of the Company’s intangible asset license had not yet commenced (see Note 6). The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates. For stock-based compensation awards to non-employees, the Company remeasures the fair value of the unvested non-employee awards at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value of these non-employee awards are recognized as compensation expense in the period of change. The Company estimates the fair value of stock options grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if it is more likely than not that the deferred tax assets will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50 Non-controlling interests in consolidated entities represent the component of equity in consolidated entities held by third parties. Any change in ownership of a subsidiary while the controlling financial interest is retained is accounted for as an equity transaction between the controlling and non-controlling interests (see Note 5). The Company’s comprehensive loss is equal to its net loss for all periods presented. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern In January 2015, the FASB issued ASU 2015-01, Income Statement – Extraordinary and Unusual Items In the first quarter of 2015, the Company adopted ASU No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs In August 2015, the FASB issued ASU No. 2015-15, Interest - Imputation of Interest

Marketable Securities

Marketable Securities	9 Months Ended
	Sep. 30, 2015
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	3. Marketable Securities As of September 30, 2015 ($ in thousands) Cost Unrealized Gain/(Loss) Fair Value U.S. treasury bill $ 39,940 $ 11 $ 39,951 As of December 31, 2014 ($ in thousands) Cost Unrealized Gain/(Loss) Fair Value U.S. treasury bill $ 19,998 $ - $ 19,998 Mutual fund 4 - 4 $ 20,002 $ - $ 20,002 The contractual term to maturity of all marketable securities held by the Company as of September 30, 2015 is less than one year.

Licenses Acquired

Licenses Acquired	9 Months Ended
	Sep. 30, 2015
Licenses Acquired [Abstract]
Licenses Acquired	4. Licenses Acquired In accordance with ASC 730-10-25-1, Research and Development 10.9 are comprised of the following: For the Three For the Nine Months Ended Months Ended ($ in thousands) September 30, 2015 September 30, 2015 Fortress: IV Tramadol (1) $ - $ 3,000 Fortress Companies: Mustang - 2,147 Checkpoint 600 2,633 Coronado SO - 1,607 Helocyte - 200 Escala 1,295 1,295 Total $ 1,895 $ 10,882 (1) Fortress intends to transfer IV Tramadol to Avenue. Research and Development Licenses Acquired - Fortress Companies Checkpoint Therapeutics, Inc. License Agreement with Dana-Farber Cancer Institute In March 2015, Checkpoint entered into a license agreement with Dana-Farber to develop a portfolio of fully human immuno-oncology targeted antibodies. Under the terms of the agreement, Checkpoint paid Dana-Farber an up-front licensing fee of $ 1.0 500,000 Effective March 2015, the Company assigned all of its rights under its agreement with NeuPharma to develop and commercialize novel irreversible, third generation EGFR inhibitors on a worldwide basis other than certain Asian countries, to Checkpoint in exchange for debt (see Note 8). Under the terms of the agreement, Fortress paid NeuPharma an upfront licensing fee of $ 1.0 Dr. Marasco, a professor in the Department of Cancer Immunology and AIDS at Dana-Farber whose laboratory generated the immune-oncology targeted antibodies, will chair Checkpoint’s Scientific Advisory Board. As payment for these services, in March 2015, Checkpoint granted Dr. Marasco 1,500,000 0.2 The Company valued the restricted stock Checkpoint granted to Dr. Marasco as of September 30, 2015 utilizing a market approach, based upon a third party financing (see Note 8), resulting in a value of $ 4.39 83 1.54 25 48 During the three and nine months ended September 30, 2015, Checkpoint recorded expense of approximately $ 2.7 In connection with its license agreement with Dana-Farber, Checkpoint granted Dana-Farber 500,000 44.8 30 0.065 32,500 136,803 0.6 0.6 Collaboration Agreements with TG Therapeutics, Inc. In connection with its license agreement with Dana-Farber, Checkpoint entered into a collaboration agreement with TGTX to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. Under the terms of the collaboration agreement, Checkpoint retains the right to develop and commercialize these antibodies in the field of solid tumors. Both programs are currently in pre-clinical development. TGTX paid Checkpoint $ 0.5 recognized nil and $ 0.5 In connection with its license with NeuPharma, Checkpoint entered into an option with TGTX for $ 25,000 Mustang Bio, Inc. License Agreement with the City of Hope In March 2015, Mustang entered into a license agreement with the COH to acquire CAR-T technology. Pursuant to the agreement, in April 2015, Mustang paid the COH an upfront fee of $ 2.0 1,000,000 2.0 The Company valued the stock grant to the COH utilizing a discounted cash flow model to determine the weighted market value of invested capital, discounted by a lack of marketability of 44.8%, weighted average cost of capital of 30 0.147 0.1 0.1 Coronado SO Company License Agreement In February 2015, Coronado SO entered into an exclusive license agreement with a third party for a topical product used in the treatment of Hand-Foot Syndrome, a common painful side effect of chemotherapeutics. Coronado SO paid $ 0.9 150,000 0.5 The Company valued the stock grant to the third party utilizing a discounted cash flow model to determine the weighted market value of invested capital, discounted by a lack of marketability of 44.8 30 1.19 0.2 1.6 Avenue Therapeutics, Inc. License Agreement with Revogenex Ireland Ltd In February 2015, the Company purchased an exclusive license to IV Tramadol for the U.S. market from Revogenex, a privately held company in Dublin, Ireland. Fortress made an upfront payment of $ 2.0 1.0 The Company intends to transfer the IV Tramadol license and rights to Avenue during the fourth quarter of 2015 in order to establish a Fortress Company focused on the acquisition, license, development and commercialization of products principally for use in the acute/intensive care hospital setting. During the second quarter of 2015, Avenue granted 150,000 1 grant vests 50% in four annual equal tranches of 12.5%, with the remaining 50% vesting upon the achievement of certain performance goals. 14,700 37,600 The Company valued the stock utilizing a discounted cash flow model to determine the weighted market value of invested capital, discounted by a lack of marketability of 44.8 30 0.146 Helocyte, Inc. License Agreement with the City of Hope On April 2, 2015, Helocyte entered into an agreement with the COH to secure the exclusive license to the worldwide rights for two T-cell immunotherapeutic vaccines for controlling CMV in HSCT and SOT recipients, for an upfront payment of $ 150,000 500,000 50,000 0.2 Escala Therapeutics, Inc. On July 16, 2015, Escala acquired from NZP a license from the NIH and CRADAs for the development of oral ManNAc, a key compound in the sialic biosynthetic pathway, for the treatment of hyposialylation disorders, including GNE myopathy and various forms of nephropathy. As part of this agreement, Escala provided NZP and NIH an upfront payment of approximately $ 1.3 0.7 0.6 1.3

Non-Controlling Interests

Non-Controlling Interests	9 Months Ended
	Sep. 30, 2015
Noncontrolling Interest [Abstract]
Non-Controlling Interests	5. Non-Controlling Interests ($ in thousands) As of September 30, 2015 Avenue Coronado SO Mustang Checkpoint JMC Total NCI equity share $ 4 $ 23 $ 15 $ 4,076 $ (392) $ 3,726 Net loss attributed to non-controlling interest (401) (237) (321) (1,168) (289) (2,416) Non-controlling in consolidated entities $ (397) $ (214) $ (306) $ 2,908 $ (681) $ 1,310 ($ in thousands) For the three months ended September 30, 2015 Avenue Coronado SO Mustang Checkpoint JMC Total Non-controlling interests in loss of consolidated entities $ (367) $ (7) $ (54) $ (977) $ (289) $ (1,694) Non-controlling ownership (See Note 4) 11.5 % 13 % 10 % 20.0 % 25.0 % ($ in thousands) For the nine months ended September 30, 2015 Avenue Coronado SO Mustang Checkpoint JMC Total Non-controlling interests in loss of consolidated entities $ (401) $ (237) $ (321) $ (1,168) $ (289) $ (2,416) Non-controlling ownership (See Note 4) 11.5 % 13 % 10 % 20.0 % 25.0 %

Intangible Asset License

Intangible Asset License	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Asset License	6. Intangible Asset License Journey Medical Corporation In March 2015, JMC entered into a license and supply agreement to acquire the rights to distribute a dermatological product for the treatment of acne. JMC made an upfront payment of $ 1.3 0.7 The Company recorded the upfront payment as an intangible asset on the unaudited condensed consolidated balance sheet and will amortize it over the deemed life of the product or agreement (whichever is shorter) upon the commencement of sales, which the Company expects in late 2015 or early 2016. The product is fully developed and approved but sales cannot commence until manufacturing regulatory clearance is obtained.

Net Loss Per Common Share

Net Loss Per Common Share	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Net Loss Per Common Share	7. Net Loss per Common Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock and common stock equivalents outstanding for the period. For the three months ended For the nine months ended ($ in thousands except share and per share amounts) 2015 2014 2015 2014 Net loss attributable to common stockholders (18,161) (4,592) (36,392) (16,673) Weighted average common shares outstanding—basic and diluted 39,412,056 36,024,810 39,038,522 35,977,355 Basic and diluted net loss per common share $ (0.46) $ (0.13) $ (0.93) $ (0.46) Included in common stock issued and outstanding as of September 30, 2015 are 7,670,935 The Company’s potential dilutive securities which consist of unvested restricted stock, options, and warrants have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average common stock outstanding used to calculate both basic and diluted net loss per share is the same. For the three months ended For the nine months ended September 30, September 30, 2015 2014 2015 2014 Warrants to purchase Common Stock 685,061 685,061 685,061 696,526 Options to purchase Common Stock 1,832,499 2,171,032 2,019,219 2,312,461 Unvested Restricted Stock 6,884,631 6,308,038 6,795,132 5,880,063 Unvested Restricted Stock Units 752,761 - 258,242 - Total 10,154,952 9,164,131 9,757,654 8,889,050

Debt and Interest

Debt and Interest	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Debt and Interest	8. Debt and Interest Debt ($ in Thousands) September 30, 2015 December 31, 2014 Interest Rate Maturity IDB Note $ 14,009 $ 14,009 2.25 % Feb - 2017 NSC Note 10,000 - 8.00 % Mar - 2018 Total notes payable, long-term 24,009 14,009 Less: Discount of notes payable 718 6 Total notes payable, long-term, net $ 23,291 $ 14,003 IDB Note At September 30, 2015, the Company had $ 14.0 NSC Note In March 2015, the Company closed a private placement of a promissory note for $ 10 8 0.9 11.3 The NSC Note was amended and restated on July 29, 2015 to provide that any time a Fortress Company receives from the Company any proceeds from the NSC Note, the Company may, in its sole discretion, cause the Fortress Company to issue to NSC Biotech Venture Fund I LLC a new promissory note (the “Amended NSC Note”) on identical terms as the NSC Note, giving effect to the passage of time with respect to maturity. The Amended NSC Note will equal the dollar amount of the Fortress Company’s share of the NSC Note and reduce the Company’s obligations under the NSC Note by such amount. The Company will guarantee the Amended NSC Note until the Fortress Company either completes an initial public offering of its securities or raises sufficient equity capital so that it has cash equal to five times the Amended NSC Note. As of September 30, 2015, the Company transferred $ 2.8 In connection with the transfer of NSC Note proceeds to a Fortress Company and the removal of the Company’s guarantee of the Amended NSC Note, NSC will receive a warrant to purchase the Fortress Company’s stock equal to 25% of the NSC Note proceeds transferred to that Fortress Company divided by the lowest price at which the Fortress Company sells its equity in its first third party financing. The warrants issued will have a term of 10 Interest For the three months ended For the nine months ended ($ in thousands) 2015 2014 2015 2014 IDB Note Interest $ 82 $ 81 $ 235 $ 202 Amortization of fees 1 1 3 3 Total IDB Note 83 82 238 205 NSC Debt Interest 208 - 488 - Amortization of fees 59 - 140 - Total NSC Debt 267 - 628 - Ovamed Manufacturing Agreement Interest - 39 167 114 Total Ovamed - 39 167 114 Hercules Debt Interest (1) - - - 845 Amortization of fees - - - 42 Total Hercules Debt - - - 887 Total Interest Expense $ 350 $ 121 $ 1,033 $ 1,206 (1) Interest expense related to the Company’s loan with Hercules was $ 0.8 0.4

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2015
Property Plant And Equipment [Abstract]
Property and Equipment	9. Property and Equipment As of September 30, As of December 31, ($ in thousands) Useful Life (Years) 2015 2014 Computer equipment 3 $ 13 $ 13 Furniture & fixtures 5 69 69 Leasehold improvements 5 12 12 Construction in progress N/A 94 - Total property and equipment 188 94 Less: Accumulated depreciation (59) (42) Property and equipment, net $ 129 $ 52 Depreciation expense for the three months ended September 30, 2015 and 2014 was approximately $ 5,700 6,000 17,100 17,000

Accrued Expenses and Other Long

Accrued Expenses and Other Long-Term Liabilities	9 Months Ended
	Sep. 30, 2015
Payables and Accruals [Abstract]
Accrued Expenses and Other Long-Term Liabilities	10. Accrued Expenses and Other Long-Term Liabilities In December 2012, the Company acquired certain manufacturing rights from Ovamed GmbH (“Ovamed”) and agreed to pay an aggregate of $ 1.5 0.5 1.5 39,000 167,000 114,000 The Company also had a collaboration agreement with Dr. Falk Pharma (“Falk”) in connection with the development of TSO. Under this agreement, Falk was to provide the Company with the Final Clinical Study Report (“CSR”). On August 3, 2015, Falk notified the Company that the CSR was complete and that Falk was prepared to grant the Company access to the CSR. While the Company disputes the adequacy of the CSR and does not believe any payment is due to Falk, upon receipt of access to the CSR, the Company recorded a liability of € 2.5 2.8 September 30, 2015 December 31, 2014 Accrued expenses: Professional fees $ 302 $ 837 Salaries, bonuses and related benefits 961 598 Accrued milestone, CNDO SO 500 - Accrued severance 6 38 Ovamed manufacturing rights - short term component 1,500 1,000 Clinical Study Report 2,823 - Research and development 589 832 Lease impairment 165 165 Other 291 213 Total accrued expenses $ 7,137 $ 3,683 Other long-term liabilities: Ovamed manufacturing rights – long-term component - 334 Long-term lease abandonment charge 82 268 Deferred rent 120 120 Total other long-term liabilities $ 202 $ 722

Investments at Fair Value

Investments at Fair Value	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Investments at Fair Value	11. Investments at Fair Value From time to time, the Company invests in marketable securities, which are classified as trading securities and are stated at fair value as determined by quoted market prices. As of both September 30, 2015 and December 31, 2014, the Company held approximately $ 40.0 20.0 The fair value of the Company’s investment of $ 250,000 0.2 As of September 30, 2015, the Company valued its investment in CB Pharma, a publicly traded company, utilizing the following assumptions: volatility of 25.4 8.99 9.49 25.4 1.37 11.50 arriving at a value of $ 0.95 0.84 31.69 2.84 3.00 0.27 0.30 1.4 3.8 42.6 0.5 0.1 50 Certain of the Company’s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities. Fair Value Measurement as of September 30, 2015 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Marketable securities: U.S. treasury bills $ 39,951 $ - $ - $ 39,951 Total marketable securities 39,951 - - 39,951 Long-term investments, at fair value - - 4,095 4,095 Total $ 39,951 $ - $ 4,095 $ 44,046 Fair Value Measurement as of December 31, 2014 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Marketable securities: U.S. treasury bills $ 19,998 $ - $ - $ 19,998 Mutual funds 4 - 4 Total marketable securities 20,002 - - 20,002 Long-term investments, at fair value - - 4,160 4,160 Total $ 20,002 $ - $ 4,160 $ 24,162 The fair value of marketable securities are determined using quoted market prices from daily exchange-traded markets based on the closing price as of the balance sheet date. Fair Value of Investment Short-term Long-term Total ($ in thousands) Other Other CB Pharma Balance at December 31, 2014 $ - $ 250 $ 3,910 $ 4,160 Change in fair value of investment - - (65) (65) Balance at September 30, 2015 $ - $ 250 $ 3,845 $ 4,095 For the three and nine months ended September 30, 2015, no transfers occurred between Level 1, Level 2 and Level 3 instruments.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2015
Stockholders' Equity Note [Abstract]
Stockholders’ Equity	Stock-based Compensation As of September 30, 2015, the Company had four equity compensation plans: the Fortress Biotech, Inc. 2007 Stock Incentive Plan, the Fortress Biotech, Inc. 2013 Stock Incentive Plan, the Fortress Biotech, Inc. 2012 Employee Stock Purchase Plan and the Fortress Biotech. Inc. Long Term Incentive Plan (“LTIP”). For the three months ended For the nine months ended September 30, September 30, ($ in thousands) 2015 2014 2015 2014 Employee awards $ 3,296 $ 1,460 $ 6,284 $ 4,035 Executive awards of Fortress Companies' stock 2,229 - 2,229 - Non-employee awards 10 24 24 47 Fortress Companies (1) 2,966 - 3,359 - Total stock-based compensation expense $ 8,501 $ 1,484 $ 11,896 $ 4,082 (1) Includes for Avenue $ 37,600 178,500 0.6 2.1 147,000 279,500 September 30, 2015 For the three months ended September 30, 2015, $ 4.3 3.7 0.6 4.2 0.5 2.2 Companies’ common stock granted to the Company’s Chief Executive Officer and Executive Vice Chairman. For the three months ended September 30, 2014, $ 0.3 1.2 For the nine months ended September 30, 2015 and 2014, $ 5.2 4.3 0.9 and $ 6.7 0.9 3.1 The following table summarizes Fortress stock option activities excluding activity related to Fortress Companies: Weighted average Weighted average Total weighted average remaining contractual ($ in thousands) Number of shares exercise price intrinsic value life (years) Options vested and expected to vest at December 31, 2014 2,164,365 $ 4.69 $ - 7.38 Options granted - - - Options exercised (100,000) 2.15 45 Options cancelled (285,000) 7.57 1,417 Options vested and expected to vest at September 30, 2015 1,779,365 $ 4.37 $ - 6.57 Options vested and exercisable 1,632,698 $ 4.40 $ - 6.45 0.1 0.20 George Avgerinos Grant On July 15, 2015, George Avgerinos, Senior Vice President, Biologics Operations, was granted 1.0 50 200,000 3.3 0.4 3.7 300,000 1.4 Acceleration of David Barrett Grants On July 15, 2015, the Board of Directors voted to accelerate the vesting of 133,000 0.4 Restricted Stock Unit Grant to Dov Klein On July 15, 2015, Dov Klein joined the Board of Directors of Fortress. In connection therewith Fortress granted Mr. Klein 50,000 25 40,000 Weighted Number of shares price Unvested balance at December 31, 2014 8,287,384 $ 2.33 Restricted stock granted 200,000 3.04 Restricted stock vested (816,449) 2.69 Restricted stock units granted 1,412,000 3.58 Restricted stock units vested (335,000) 3.56 Unvested balance at September 30, 2015 8,747,935 $ 2.53 As of September 30, 2015, the Company had unrecognized stock-based compensation expense related to restricted stock and restricted stock unit awards of $ 10.1 3.2 1.95 1.4 Warrants As of September 30, 2015 and December 31, 2014, the Company had vested warrants to purchase 685,061 6.65 Deferred Compensation Plan On March 12, 2015, the Company’s Compensation Committee approved the Deferred Compensation Plan allowing all non-employee directors the opportunity to defer all or a portion of their fees or compensation, including restricted stock and restricted stock units. During the nine months ended September 30, 2015, certain non-employee directors elected to defer 290,000 Employee Stock Purchase Plan As of September 30, 2015, 77,875 122,125 12,600 4,200 27,500 19,900 Long-Term Incentive Program At the Company’s annual stockholders meeting held on July 15, 2015, the stockholders approved the Fortress Biotech, Inc. Long-Term Incentive Plan (the “LTIP”) for the Company’s Chairman, President and Chief Executive Officer, Dr. Rosenwald, and Executive Vice Chairman, Strategic Development, Mr. Weiss. The LTIP consists of a program to grant equity interests in the Company and newly formed subsidiaries and a performance-based bonus program that is designed to result in performance-based compensation that is deductible without limit under Section 162(m) of the Internal Revenue Code of 1986, as amended. 500,000 Fortress Stock Warrant Shares Risk Free Rate Volatilty Life Exercise price Fair Value Mustang 1,000,000 2.36 % 106.11 % 20 $ 0.147 $ 135 Checkpoint 1,000,000 2.36 % 106.11 % 20 $ 0.129 $ 118 Avenue 1,000,000 2.36 % 106.11 % 20 $ 0.146 $ 134 CNDO SO 1,000,000 2.36 % 106.11 % 20 $ 1.190 $ 1,092 Helocyte 1,000,000 2.36 % 106.11 % 20 $ 0.097 $ 89 JMC 1,000,000 2.36 % 106.11 % 20 $ 0.650 $ 596 Escala 1,000,000 2.36 % 106.11 % 20 $ 0.071 $ 65 The exercise price, which approximates the fair value, was determined by 44.8 30 Fortress Companies Checkpoint Therapeutics, Inc. In March 2015, Checkpoint issued a restricted stock grant to Dr. Marasco for services in connection with its Scientific Advisory Board. Dr. Marasco was issued a grant for 1.5 25 48 4.39 83 1.54 2.1 Avenue Therapeutics, Inc. During the nine months ended September 30, 2015, Avenue granted 150,000 1.0 44.8 30 0.146 50 12.5 50 15,000 37,600 As of September 30, 2015 Avenue had unrecognized stock-based compensation expense of $64,570 with a remaining weighted average vesting period of 1.67 years. Journey Medical Corporation On July 28, 2015, JMC granted 1,950,000 44.5 30 0.65 RSU Grant Vesting Term Vested Unvested Fair Value per Share President (1) 1,500,000 4 250,000 1,250,000 $ 0.650 Sales Operations Staff 450,000 4 - 450,000 $ 0.650 1,950,000 250,000 1,700,000 (1) Vesting is performance based. Expense for both the three and nine months ended September 30, 2015 of approximately $ 279,000 As of September 30, 2015, JMC had unrecognized stock-based compensation expense of $ 0.5 1.07 Capital Raise On September 30, 2015, a subsidiary of Fortress closed the first tranche of a confidential private placement offering raising approximately $ 12.6 1.5 .

Related Party Note

Related Party Note	9 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
Related Party Note	13. Related Party Note Related Party Service Agreement Services Agreement with Opus Point Management Partners, LLC On April 3, 2014, the Company entered into a Shared Services Agreement with OPPM in which the parties agreed to share a rented facility as well as costs for certain services, which they individually require for the operation of their respective entities. The Company’s Chairman, President and Chief Executive Officer and the Company’s Executive Vice Chairman, Strategic Development are both Co-Portfolio Managers and Partners of OPPM. The Company incurred expense of approximately $ 66,000 153,700 40,000 79,000 Shared Services Agreement with TGTX In September 2014, the Company entered into a desk share agreement with TGTX. The Company’s Executive Vice Chairman, Strategic Development, is Executive Chairman and Interim Chief Executive Officer of TGTX. Under the terms of the Agreement, TGTX will share costs associated with this facility, which is expected to be occupied during the first half of 2016. Additionally, in July 2015, TGTX and the Company entered into an arrangement to share the cost of a research and development full-time employee. The salary and benefit costs associated with this employee are allocated based on hours worked in connection with TGTX projects. The Company received payments of $ 71,800 69,300 Checkpoint Collaboration Agreement with TGTX In connection with the license agreement with Dana-Farber, Checkpoint entered into a collaboration agreement with TGTX to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. In connection with this Agreement, TGTX paid Checkpoint an upfront fee of $ 0.5 Further in connection with the NeuPharma license, Checkpoint entered into an option agreement with TGTX for $25,000, included in revenue, for a global collaboration in connection with the future development of the certain compounds licensed. The option expires on December 17, 2015. Founders Agreement and Management Services Agreement with Checkpoint Effective March 17, 2015, the Company entered into a Founders Agreement with Checkpoint pursuant to which the Company assigned to Checkpoint all of its right and interest (i) under the Company’s license agreement for the EGFR inhibitors and (ii) to a license agreement currently under negotiation, as set forth in the Founders Agreement. As consideration for the Founders Agreement, Checkpoint assumed $ 2.8 issue annually to the Company, on the anniversary date of the Founders Agreement, shares of Checkpoint common stock equal to 2.25% of the fully-diluted outstanding equity of Checkpoint at the time of issuance; (ii) pay an equity fee in shares of Checkpoint common stock, payable within five (5) business days of the closing of any equity or debt financing for Checkpoint or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when the Company no longer has majority voting control in Checkpoint’s voting equity, equal to 2.25% of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to 4.5% of its annual net sales, payable on an annual basis, within 90 days of the end of each calendar year. In the event of a change in control (as defined in the Founders Agreement), the Company will pay a one-time change in control fee equal to five times (5x) the product of (i) monthly net sales for the 12 months immediately preceding the change in control and (ii) 4.5% CB Pharma Acquisition Corp. The Company has committed to provide working capital of up to $ 0.5 0.1

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events In October 2015, the Company provided an additional $ 50,000 On October 30, 2015, a subsidiary of Fortress closed the second tranche of a confidential private placement offering raising approximately $ 12.6 1.3

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on March 16, 2015 and amended on April 30, 2015, from which the Company derived the balance sheet data at December 31, 2014. The Company’s unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries: Innmune Limited, Coronado SO, Cyprium Therapeutics, Inc., Escala, JMC, CB Securities Corporation, Avenue, Checkpoint, Mustang and Helocyte. All intercompany balances and transactions have been eliminated. The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period.
Use of Estimates	Use of Estimates The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.
Reclassifications	Reclassifications The Company reclassified debt issuance costs from other assets to notes payable, long-term, net on the unaudited condensed consolidated balance sheets for all periods presented pursuant to the early adoption of Accounting Standards Update (“ASU”) No. 2015-03 - Simplifying the Presentation of Debt Issuance Costs
Restricted Cash	Restricted Cash The Company records cash held in trust or pledged to secure certain debt obligations as restricted cash. As of September 30, 2015, the Company has $ 14.6 14.0 0.6
Fair Value Measurement	Fair Value Measurement The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories: Level 1 : Quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Certain of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities. The carrying value of the amount owed to Ovamed GmbH (“Ovamed”) upon the acquisition of certain manufacturing rights in December 2012 under the amendment to the sublicense agreement with Ovamed included in current liabilities in the September 30, 2015 unaudited condensed consolidated balance sheet and both current liabilities and long-term liabilities in the December 31, 2014 consolidated balance sheet, has been recorded at its net present value, which approximates its fair value (see Note 10).
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. During the nine month period ended September 30, 2014, in relation to the abandonment of its lease in Woburn, MA, the Company recorded an impairment loss of $ 0.4
Investments at Fair Value	Investments at Fair Value The Company elected the fair value option for its investment in a third-party company developing a laser device to treat migraine headaches, and its investment in CB Pharma Acquisition Corp. (“CB Pharma”). As of September 30, 2015, the fair value of these investments approximate $ 4.1 While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The decision to elect the fair value option, which is irrevocable once elected, is determined on an instrument by instrument basis and applied to an entire instrument. The net gains or losses, if any, on an investment for which the fair value option has been elected, are recognized as a change in fair value of investments in the unaudited condensed consolidated statements of operations.
Revenue Recognition	Revenue Recognition Reimbursement Arrangements The Company, via the collaboration agreement between Checkpoint and TGTX, is reimbursed by TGTX for its share of the cost of the license and future milestone payments that are payable to Dana-Farber pursuant to the license agreement (for further discussion, see Note 1). The gross amount of these reimbursed costs are reported as revenue in the accompanying unaudited condensed consolidated statements of operations. The Company acts as a principal (as the Company is responsible for designing the future clinical development pathway), bears credit risk and may perform part of the services required in the transactions. Consistent with ASC 605-45, Revenue Recognition – Principal Agent Considerations, Collaborative Arrangements The Company recognizes revenue for the performance of services or the shipment of products when each of the following four criteria is met: (i) persuasive evidence of an arrangement exists; (ii) products are delivered or as services are rendered; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured. The Company follows ASC 605-25, Revenue Recognition – Multiple-Element Arrangements Collaborative Arrangements ASC 605-25 provides guidance relating to the separability of deliverables included in an arrangement into different units of accounting and the allocation of arrangement consideration to the units of accounting. The evaluation of multiple-element arrangements requires management to make judgments about (i) the identification of deliverables, (ii) whether such deliverables are separable from the other aspects of the contractual relationship, (iii) the estimated selling price of each deliverable, and (iv) the expected period of performance for each deliverable. To determine the units of accounting under a multiple-element arrangement, management evaluates certain separation criteria, including whether the deliverables have stand-alone value, based on the relevant facts and circumstances for each arrangement. Management then estimates the selling price for each unit of accounting and allocates the arrangement consideration to each unit utilizing the relative selling price method. The allocated consideration for each unit of accounting is recognized over the related obligation period in accordance with the applicable revenue recognition criteria. If there are deliverables in an arrangement that are not separable from other aspects of the contractual relationship, they are treated as a combined unit of accounting, with the allocated revenue for the combined unit recognized in a manner consistent with the revenue recognition applicable to the final deliverable in the combined unit. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as deferred revenue in the condensed consolidated balance sheets and recognized as revenue in the condensed consolidated statements of operations when the related revenue recognition criteria are met. See Note 4 for a description of the collaborative arrangements.
Intangible Asset License	Intangible Asset License The Company records the costs of acquired product license rights as intangible asset licenses in the condensed consolidated balance sheets. Upon commencement of product sales, license rights will be amortized over the expected life of the product into product expense in the condensed consolidated statements of operations. As of September 30, 2015, product sales of the Company’s intangible asset license had not yet commenced (see Note 6).
Stock-Based Compensation	Stock-Based Compensation The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates. For stock-based compensation awards to non-employees, the Company remeasures the fair value of the unvested non-employee awards at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value of these non-employee awards are recognized as compensation expense in the period of change. The Company estimates the fair value of stock options grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment.
Income Taxes	Income Taxes The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if it is more likely than not that the deferred tax assets will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50
Non-Controlling Interests	Non-Controlling Interests Non-controlling interests in consolidated entities represent the component of equity in consolidated entities held by third parties. Any change in ownership of a subsidiary while the controlling financial interest is retained is accounted for as an equity transaction between the controlling and non-controlling interests (see Note 5).
Comprehensive Loss	Comprehensive Loss The Company’s comprehensive loss is equal to its net loss for all periods presented.
Recently Issued Accounting Standards	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern In January 2015, the FASB issued ASU 2015-01, Income Statement – Extraordinary and Unusual Items In the first quarter of 2015, the Company adopted ASU No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs In August 2015, the FASB issued ASU No. 2015-15, Interest - Imputation of Interest

Marketable Securities (Tables)

Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2015
Marketable Securities [Abstract]
Marketable Securities	Marketable securities, classified as trading, consist of the following: As of September 30, 2015 ($ in thousands) Cost Unrealized Gain/(Loss) Fair Value U.S. treasury bill $ 39,940 $ 11 $ 39,951 As of December 31, 2014 ($ in thousands) Cost Unrealized Gain/(Loss) Fair Value U.S. treasury bill $ 19,998 $ - $ 19,998 Mutual fund 4 - 4 $ 20,002 $ - $ 20,002

Licenses Acquired (Tables)

Licenses Acquired (Tables)	9 Months Ended
	Sep. 30, 2015
Research and Development [Abstract]
Research and Development Arrangement, Contract to Perform for Others	are comprised of the following: For the Three For the Nine Months Ended Months Ended ($ in thousands) September 30, 2015 September 30, 2015 Fortress: IV Tramadol (1) $ - $ 3,000 Fortress Companies: Mustang - 2,147 Checkpoint 600 2,633 Coronado SO - 1,607 Helocyte - 200 Escala 1,295 1,295 Total $ 1,895 $ 10,882 (1) Fortress intends to transfer IV Tramadol to Avenue.

Non-Controlling Interests (Tabl

Non-Controlling Interests (Tables)	9 Months Ended
	Sep. 30, 2015
Noncontrolling Interest [Abstract]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net	Non-controlling interests in consolidated entities are as follows: ($ in thousands) As of September 30, 2015 Avenue Coronado SO Mustang Checkpoint JMC Total NCI equity share $ 4 $ 23 $ 15 $ 4,076 $ (392) $ 3,726 Net loss attributed to non-controlling interest (401) (237) (321) (1,168) (289) (2,416) Non-controlling in consolidated entities $ (397) $ (214) $ (306) $ 2,908 $ (681) $ 1,310
Components Of Non-Controlling Interests In Loss Of Consolidated Entities	The components of non-controlling interests in loss of consolidated entities are as follows: ($ in thousands) For the three months ended September 30, 2015 Avenue Coronado SO Mustang Checkpoint JMC Total Non-controlling interests in loss of consolidated entities $ (367) $ (7) $ (54) $ (977) $ (289) $ (1,694) Non-controlling ownership (See Note 4) 11.5 % 13 % 10 % 20.0 % 25.0 % ($ in thousands) For the nine months ended September 30, 2015 Avenue Coronado SO Mustang Checkpoint JMC Total Non-controlling interests in loss of consolidated entities $ (401) $ (237) $ (321) $ (1,168) $ (289) $ (2,416) Non-controlling ownership (See Note 4) 11.5 % 13 % 10 % 20.0 % 25.0 %

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Calculation of Basic and Diluted Net Loss Per Share	A calculation of basic and diluted net loss per common share follows: For the three months ended For the nine months ended ($ in thousands except share and per share amounts) 2015 2014 2015 2014 Net loss attributable to common stockholders (18,161) (4,592) (36,392) (16,673) Weighted average common shares outstanding—basic and diluted 39,412,056 36,024,810 39,038,522 35,977,355 Basic and diluted net loss per common share $ (0.46) $ (0.13) $ (0.93) $ (0.46)
Computations of Diluted Weighted Average Shares Outstanding	The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding, as the effect of including such securities would be anti-dilutive: For the three months ended For the nine months ended September 30, September 30, 2015 2014 2015 2014 Warrants to purchase Common Stock 685,061 685,061 685,061 696,526 Options to purchase Common Stock 1,832,499 2,171,032 2,019,219 2,312,461 Unvested Restricted Stock 6,884,631 6,308,038 6,795,132 5,880,063 Unvested Restricted Stock Units 752,761 - 258,242 - Total 10,154,952 9,164,131 9,757,654 8,889,050

Debt and Interest (Tables)

Debt and Interest (Tables)	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Schedule Of Interest Expenses	Long-term debt consists of the following as of September 30, 2015 and December 31, 2014: ($ in Thousands) September 30, 2015 December 31, 2014 Interest Rate Maturity IDB Note $ 14,009 $ 14,009 2.25 % Feb - 2017 NSC Note 10,000 - 8.00 % Mar - 2018 Total notes payable, long-term 24,009 14,009 Less: Discount of notes payable 718 6 Total notes payable, long-term, net $ 23,291 $ 14,003
Schedule Of Interest Expenses For Debt Arrangements	The following table shows the details of interest expense for all debt arrangements during the periods presented. Interest expense includes contractual interest and amortization of the debt discount and amortization of fees represents fees associated with loan transaction costs, amortized over the life of the loan: For the three months ended For the nine months ended ($ in thousands) 2015 2014 2015 2014 IDB Note Interest $ 82 $ 81 $ 235 $ 202 Amortization of fees 1 1 3 3 Total IDB Note 83 82 238 205 NSC Debt Interest 208 - 488 - Amortization of fees 59 - 140 - Total NSC Debt 267 - 628 - Ovamed Manufacturing Agreement Interest - 39 167 114 Total Ovamed - 39 167 114 Hercules Debt Interest (1) - - - 845 Amortization of fees - - - 42 Total Hercules Debt - - - 887 Total Interest Expense $ 350 $ 121 $ 1,033 $ 1,206 (1) Interest expense related to the Company’s loan with Hercules was $ 0.8 0.4

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2015
Property Plant And Equipment [Abstract]
Components of Property and Equipment	Property and equipment consisted of the following: As of September 30, As of December 31, ($ in thousands) Useful Life (Years) 2015 2014 Computer equipment 3 $ 13 $ 13 Furniture & fixtures 5 69 69 Leasehold improvements 5 12 12 Construction in progress N/A 94 - Total property and equipment 188 94 Less: Accumulated depreciation (59) (42) Property and equipment, net $ 129 $ 52

Accrued Expenses and Other Lo27

Accrued Expenses and Other Long-Term Liabilities (Tables)	9 Months Ended
	Sep. 30, 2015
Payables and Accruals [Abstract]
Components of Accrued Expenses and Other Long-Term Liabilities	Accrued expenses and other long-term liabilities consisted of the following: September 30, 2015 December 31, 2014 Accrued expenses: Professional fees $ 302 $ 837 Salaries, bonuses and related benefits 961 598 Accrued milestone, CNDO SO 500 - Accrued severance 6 38 Ovamed manufacturing rights - short term component 1,500 1,000 Clinical Study Report 2,823 - Research and development 589 832 Lease impairment 165 165 Other 291 213 Total accrued expenses $ 7,137 $ 3,683 Other long-term liabilities: Ovamed manufacturing rights – long-term component - 334 Long-term lease abandonment charge 82 268 Deferred rent 120 120 Total other long-term liabilities $ 202 $ 722

Investments at Fair Value (Tabl

Investments at Fair Value (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables classify into the fair value hierarchy financial instruments measured at fair value on a recurring basis in the accompanying condensed consolidated balance sheets as of September 30, 2015 (unaudited) and December 31, 2014: Fair Value Measurement as of September 30, 2015 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Marketable securities: U.S. treasury bills $ 39,951 $ - $ - $ 39,951 Total marketable securities 39,951 - - 39,951 Long-term investments, at fair value - - 4,095 4,095 Total $ 39,951 $ - $ 4,095 $ 44,046 Fair Value Measurement as of December 31, 2014 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Marketable securities: U.S. treasury bills $ 19,998 $ - $ - $ 19,998 Mutual funds 4 - 4 Total marketable securities 20,002 - - 20,002 Long-term investments, at fair value - - 4,160 4,160 Total $ 20,002 $ - $ 4,160 $ 24,162
Schedule of changes in fair value of financial instruments	The table below provides a roll-forward of the changes in fair value of Level 3 financial instruments, as of September 30, 2015: Fair Value of Investment Short-term Long-term Total ($ in thousands) Other Other CB Pharma Balance at December 31, 2014 $ - $ 250 $ 3,910 $ 4,160 Change in fair value of investment - - (65) (65) Balance at September 30, 2015 $ - $ 250 $ 3,845 $ 4,095

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Share-based Compensation, Activity	The following table summarizes the stock-based compensation expense from stock option awards, restricted common stock awards, employee stock purchase programs and warrants granted by Fortress for the three and nine months ended September 30, 2015 and 2014: For the three months ended For the nine months ended September 30, September 30, ($ in thousands) 2015 2014 2015 2014 Employee awards $ 3,296 $ 1,460 $ 6,284 $ 4,035 Executive awards of Fortress Companies' stock 2,229 - 2,229 - Non-employee awards 10 24 24 47 Fortress Companies (1) 2,966 - 3,359 - Total stock-based compensation expense $ 8,501 $ 1,484 $ 11,896 $ 4,082 (1) Includes for Avenue $ 37,600 178,500 0.6 2.1 147,000 279,500 September 30, 2015
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes Fortress stock option activities excluding activity related to Fortress Companies: Weighted average Weighted average Total weighted average remaining contractual ($ in thousands) Number of shares exercise price intrinsic value life (years) Options vested and expected to vest at December 31, 2014 2,164,365 $ 4.69 $ - 7.38 Options granted - - - Options exercised (100,000) 2.15 45 Options cancelled (285,000) 7.57 1,417 Options vested and expected to vest at September 30, 2015 1,779,365 $ 4.37 $ - 6.57 Options vested and exercisable 1,632,698 $ 4.40 $ - 6.45
Nonvested Restricted Stock Shares Activity	The following table summarizes Fortress’ restricted stock and restricted stock unit award activity, excluding activity related to Fortress Companies: Weighted Number of shares price Unvested balance at December 31, 2014 8,287,384 $ 2.33 Restricted stock granted 200,000 3.04 Restricted stock vested (816,449) 2.69 Restricted stock units granted 1,412,000 3.58 Restricted stock units vested (335,000) 3.56 Unvested balance at September 30, 2015 8,747,935 $ 2.53
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	500,000 Fortress Stock Warrant Shares Risk Free Rate Volatilty Life Exercise price Fair Value Mustang 1,000,000 2.36 % 106.11 % 20 $ 0.147 $ 135 Checkpoint 1,000,000 2.36 % 106.11 % 20 $ 0.129 $ 118 Avenue 1,000,000 2.36 % 106.11 % 20 $ 0.146 $ 134 CNDO SO 1,000,000 2.36 % 106.11 % 20 $ 1.190 $ 1,092 Helocyte 1,000,000 2.36 % 106.11 % 20 $ 0.097 $ 89 JMC 1,000,000 2.36 % 106.11 % 20 $ 0.650 $ 596 Escala 1,000,000 2.36 % 106.11 % 20 $ 0.071 $ 65
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]	RSU Grant Vesting Term Vested Unvested Fair Value per Share President (1) 1,500,000 4 250,000 1,250,000 $ 0.650 Sales Operations Staff 450,000 4 - 450,000 $ 0.650 1,950,000 250,000 1,700,000 (1) Vesting is performance based.

Organization and Description 30

Organization and Description of Business - Additional Information (Detail) - Checkpoint Therapeutics, Inc [Member] $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)
Organization And Nature Of Business [Line Items]
Debt Issuance Cost	$ 12.6
Allocated Share-based Compensation Expense	$ 1.5

Summary of Significant Accoun31

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Accounting Policies [Line Items]
Percentage of tax benefit likely of being realized	50.00%
Restricted Cash and Cash Equivalents	$ 14.6
Gain (Loss) on Sale of Assets and Asset Impairment Charges		$ 0.4
CB Pharma Acquisitions Corp [Member]
Accounting Policies [Line Items]
Fair Value, Assets Measured on Recurring Basis, Change in Unrealized Gain (Loss)	4.1
Hercules Note Payble [Member]
Accounting Policies [Line Items]
Restricted Cash and Cash Equivalents	0.6
Debt Instrument, Periodic Payment	$ 14

Marketable Securities (Detail)

Marketable Securities (Detail) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Marketable securities, Cost			$ 20,002
Marketable securities, Unrealized Gain/(Loss)	$ 11	$ 0	0
Marketable securities, Fair value	39,951		20,002
U.S. treasury bill
Marketable securities, Cost	39,940		19,998
Marketable securities, Unrealized Gain/(Loss)	11		0
Marketable securities, Fair value	$ 39,951		19,998
Mutual fund
Marketable securities, Cost			4
Marketable securities, Unrealized Gain/(Loss)			0
Marketable securities, Fair value			$ 4

Licenses Acquired - Summary Of

Licenses Acquired - Summary Of Research and Development Arrangement Contract (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		$ 1,895	$ 0	$ 10,882	$ 0
IV Tramadol [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	[1]	0		3,000
Mustang Therapeutics, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		0		2,147
Checkpoint Therapeutics, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		600		2,633
Coronado SO Co, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		0		1,607
Helocyte [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		0		200
Escala [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		$ 1,295		$ 1,295
[1]	Fortress intends to transfer IV Tramadol to Avenue

Licenses Acquired - Additional

Licenses Acquired - Additional Information (Detail) - USD ($)	1 Months Ended			3 Months Ended			9 Months Ended
	Jul. 16, 2015	Apr. 28, 2015	Apr. 02, 2015	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments to Acquire Intangible Assets							$ 1,250,000	$ 0
Stock Issued During Period, Value, Issued for Services							1,000	4,000
Research And Development Expense				$ 9,073,000		$ 1,609,000	13,172,000	$ 8,473,000
Payments to Acquire in Process Research and Development							$ 1,600,000
Share Price				$ 9.49			$ 9.49
Scientific Advisory Board [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Stock Issued During Period, Shares, Issued for Services							1,500,000
Stock Issued During Period, Value, Issued for Services							$ 200,000
National Institutes of Health [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payment of Upfront Milestone Fees	$ 700,000
New Zealand Pharmaceuticals Ltd [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Reimbursement Revenue	600,000
Dana Farber Cancer Institute [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Marketability Percentage Of Invested Capital							44.80%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent							30.00%
Research And Development Expense				$ 600,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares							500,000
Share Price				$ 0.065			$ 0.065
Dana Farber Cancer Institute [Member] | Research and Development Expense [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research And Development Expense							$ 32,500
Escala Therapeutics, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research And Development Expense				$ 1,300,000			1,300,000
Payment of Upfront Fees	1,300,000
Reimbursement Revenue	$ 1,300,000
Collaboration Agreement with TGTX [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments for Fees							500,000
Collaboration Agreement with TGTX [Member] | NeuPharma [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments for Fees							25,000
Collaboration Agreement with TGTX [Member] | TG Therapeutics, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments for Fees							500,000
Agreement With City Of Hope [Member] | Mustang Bio, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments to Acquire in Process Research and Development							$ 2,000,000
Restricted Stock Purchase Agreement [Member] | Dana Farber Cancer Institute [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage							25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period							48 months
Chief Executive Officer [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Stock Issued During Period, Shares, Issued for Services							1
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights							grant vests 50% in four annual equal tranches of 12.5%, with the remaining 50% vesting upon the achievement of certain performance goals.
Coronado SO [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments for Fees							$ 500,000
Independent Consultant [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Share Price				$ 4.39			$ 4.39
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate							83.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate							1.54%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term							5 years
IV Tramadol [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Marketability Percentage Of Invested Capital							44.80%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent							30.00%
Share Price				$ 0.146			$ 0.146
Checkpoint Therapeutics, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research And Development Expense				$ 2,700,000			$ 2,700,000
Checkpoint Therapeutics, Inc [Member] | Dana Farber Cancer Institute [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Stock Issued During Period, Shares, Purchase of Assets							136,803
Stock Issued During Period, Value, Purchase of Assets							$ 10.9
Research And Development Expense				600,000			$ 600,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares							1,368,030
Helocyte Biosciences Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research And Development Expense				200,000			$ 200,000
Licensing Agreements [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments to Acquire Intangible Assets		$ 50,000	$ 150,000
Licensing Agreements [Member] | NeuPharma [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments for Fees							$ 1,000,000
Licensing Agreements [Member] | City Of Hope [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Marketability Percentage Of Invested Capital							83.00%
Payments for Fees							$ 2,000,000
Stock Issued During Period, Shares, Other							1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent							30.00%
Research And Development Expense				$ 100,000			$ 100,000
Share Price				$ 0.147			$ 0.147
Stock Issued During Period, Value, Other							$ 100,000
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued			500,000
Licensing Agreements [Member] | Dana Farber Cancer Institute [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments for Fees							$ 1,000,000
Licensing Agreements [Member] | Coronado SO [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Marketability Percentage Of Invested Capital							44.80%
Payments for Fees							$ 900,000
Stock Issued During Period, Shares, Other							150,000
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent							30.00%
Share Price				$ 1.19			$ 1.19
Stock Issued During Period, Value, Other							$ 200,000
Licensing Agreements [Member] | IV Tramadol [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments to Acquire Intangible Assets							1,000,000
Payments for Fees							2,000,000
Avenue Therapeutics, Inc. [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Stock Issued During Period, Value, Issued for Services				$ 14,700			37,600
Avenue Therapeutics, Inc. [Member] | Chief Executive Officer [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Stock Issued During Period, Shares, Issued for Services					1,000,000
Avenue Therapeutics, Inc. [Member] | Consultants [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Stock Issued During Period, Shares, Issued for Services				150,000	150,000
Stock Issued During Period, Value, Issued for Services				$ 15,000			$ 37,600

Non-Controlling Interests - Sum

Non-Controlling Interests - Summary Of Non-controlling Interests in Consolidated Entities (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Noncontrolling Interest [Line Items]
NCI equity share			$ 3,726
Net loss attributed to non-controlling interest	$ (1,694)	$ 0	(2,416)	$ 0
Non-controlling in consolidated entities	1,310		1,310		$ 0
Avenue [Member]
Noncontrolling Interest [Line Items]
NCI equity share			4
Net loss attributed to non-controlling interest	(367)		(401)
Non-controlling in consolidated entities	(397)		(397)
Coronado SO Co, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share			23
Net loss attributed to non-controlling interest	(7)		(237)
Non-controlling in consolidated entities	(214)		(214)
Mustang Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share			15
Net loss attributed to non-controlling interest	(54)		(321)
Non-controlling in consolidated entities	(306)		(306)
Checkpoint Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share			4,076
Net loss attributed to non-controlling interest	(977)		(1,168)
Non-controlling in consolidated entities	2,908		2,908
JMC [Member]
Noncontrolling Interest [Line Items]
NCI equity share			(392)
Net loss attributed to non-controlling interest	(289)		(289)
Non-controlling in consolidated entities	$ (681)		$ (681)

Non-Controlling Interests - S36

Non-Controlling Interests - Summary Of Components of Non-Controlling Interests in Loss of Consolidated Entities (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (1,694)	$ 0	$ (2,416)	$ 0
Avenue [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (367)		$ (401)
Non-controlling ownership (See Note 4)	11.50%		11.50%
Coronado SO Co, Inc [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (7)		$ (237)
Non-controlling ownership (See Note 4)	13.00%		13.00%
Mustang Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (54)		$ (321)
Non-controlling ownership (See Note 4)	10.00%		10.00%
Checkpoint Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (977)		$ (1,168)
Non-controlling ownership (See Note 4)	20.00%		20.00%
JMC [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (289)		$ (289)
Non-controlling ownership (See Note 4)	25.00%		25.00%

Intangible Asset License - Addi

Intangible Asset License - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Mar. 31, 2015	Sep. 30, 2015	Sep. 30, 2014
Indefinite-lived Intangible Assets [Line Items]
Payments to Acquire Intangible Assets		$ 1,250	$ 0
Journey Medical Corporation [Member]
Indefinite-lived Intangible Assets [Line Items]
Payments to Acquire Intangible Assets	$ 1,300
License Costs	$ 700

Net Loss Per Common Share - Cal

Net Loss Per Common Share - Calculation of Basic and Diluted Net Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Numerator
Net loss attributable to common stockholders	$ (18,161)	$ (4,592)	$ (36,392)	$ (16,673)
Denominator
Weighted average common shares outstanding - basic and diluted	39,412,056	36,024,810	39,038,522	35,977,355
Basic and diluted net loss per common share	$ (0.46)	$ (0.13)	$ (0.93)	$ (0.46)

Net Loss Per Common Share - Com

Net Loss Per Common Share - Computations of Diluted Weighted Average Shares Outstanding (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	10,154,952	9,164,131	9,757,654	8,889,050
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	685,061	685,061	685,061	696,526
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	1,832,499	2,171,032	2,019,219	2,312,461
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	6,884,631	6,308,038	6,795,132	5,880,063
Unvested Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	752,761	0	258,242	0

Net Loss Per Common Share - Add

Net Loss Per Common Share - Additional Information (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount	10,154,952	9,164,131	9,757,654	8,889,050
Restricted Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount			7,670,935

Debt and Interest (Detail)

Debt and Interest (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Debt [Line Items]
Total notes payable, long-term	$ 24,009	$ 14,009
Less: Discount of notes payable	718	6
Total notes payable, long-term, net	23,291	14,003
IDB Note [Member]
Debt [Line Items]
Total notes payable, long-term	$ 14,009	14,009
Interest Rate	2.25%
Maturity Date	Feb - 2017
NSC Note [Member]
Debt [Line Items]
Total notes payable, long-term	$ 10,000	$ 0
Interest Rate	8.00%
Maturity Date	Mar - 2018

Debt and Interest (Detail 1)

Debt and Interest (Detail 1) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Debt [Line Items]
Interest				$ 800
Interest expense related to the Hercules loan		$ 350	$ 121	1,033	$ 1,206
IDB Note [Member]
Debt [Line Items]
Interest		82	81	235	202
Amortization of fees		1	1	3	3
Interest and Debt Expense, Total		83	82	238	205
NSC Debt [Member]
Debt [Line Items]
Interest		208	0	488	0
Amortization of fees		59	0	140	0
Interest and Debt Expense, Total		267	0	628	0
Ovamed Manufacturing Agreement [Member]
Debt [Line Items]
Interest		0	39	167	114
Interest and Debt Expense, Total		0	39	167	114
Hercules Debt [Member]
Debt [Line Items]
Interest	[1]	0	0	0	845
Amortization of fees		0	0	0	42
Interest and Debt Expense, Total		$ 0	$ 0	$ 0	$ 887
[1]	Interest expense related to the Company’s loan with Hercules was $0.8 million, including $0.4 million related to accretion of the debt discount.

Debt and Interest- Additional I

Debt and Interest- Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Mar. 31, 2015
Debt [Line Items]
Interest Expense, Debt			$ 800
Accretion of Discount			$ 400
Debt Instrument, Interest Rate, Effective Percentage	11.30%		11.30%
IDB Promissory Note Payable [Member]
Debt [Line Items]
Notes Payable	$ 14,000		$ 14,000
NSC Notes Payable [Member]
Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	8.00%		8.00%
Fees related to the loan agreement			$ 2,800
Debt Instrument, Fee Amount	$ 900		900
Interest Expense, Debt	$ 208	$ 0	$ 488	$ 0
Notes Payable					$ 10,000
NSC [Member]
Debt [Line Items]
Debt Instrument, Term			10 years

Property and Equipment - Compon

Property and Equipment - Components of Property and Equipment (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 188	$ 94
Less: Accumulated depreciation	(59)	(42)
Property and equipment, net	129	52
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 13	13
Useful Life (Years)	3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 69	69
Useful Life (Years)	5 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 12	12
Useful Life (Years)	5 years
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 94	$ 0

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Property Plant And Equipment [Line Items]
Depreciation	$ 5,700	$ 6,000	$ 17,100	$ 17,000

Accrued Expenses and Other Lo46

Accrued Expenses and Other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Accrued expenses:
Professional fees	$ 302,000	$ 837,000
Salaries, bonuses and related benefits	961,000	598,000
Accrued milestone, CNDO SO	500,000	0
Accrued severance	6,000	38,000
Ovamed manufacturing rights - short term component	1,500,000	1,000,000
Clinical Study Report	2,823,000	0
Research and development	589,000	832,000
Lease impairment	165,000	165,000
Other	291,000	213,000
Total accrued expenses	7,137,000	3,683,000
Other long-term liabilities:
Ovamed manufacturing rights - long-term component	0	334,000
Long-term lease abandonment charge	82,000	268,000
Deferred rent	120,000	120,000
Total other long-term liabilities	$ 202,000	$ 722,000

Accrued Expenses and Other Lo47

Accrued Expenses and Other Long-Term Liabilities - Additional Information (Detail) € in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Sep. 30, 2015EUR (€)	Dec. 31, 2014USD ($)	Dec. 12, 2014USD ($)	Dec. 31, 2012USD ($)
Schedule Accrued Expenses And Other Long-Term Liabilities [Line Items]
Other Liabilities	$ 2,800,000		$ 2,800,000				€ 2.5
Other Accrued Liabilities, Current	291,000		291,000					$ 213,000
Asset Retirement Obligation, Accretion Expense	0	$ 39,000	167,000	$ 114,000
Capital Leases, Future Minimum Payments Receivable, Next Twelve Months									$ 500,000
Subsequent Event [Member]
Schedule Accrued Expenses And Other Long-Term Liabilities [Line Items]
Capital Leases, Future Minimum Payments, Receivable in Two Years						$ 500,000
Capital Leases, Future Minimum Payments, Receivable in Three Years					$ 500,000
Ovamed Manufacturing Rights [Member]
Schedule Accrued Expenses And Other Long-Term Liabilities [Line Items]
Other Liabilities										$ 1,500,000
Other Accrued Liabilities, Current	$ 1,500,000		$ 1,500,000

Fair Value Hierarchy Financial

Fair Value Hierarchy Financial Instruments Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities	$ 39,951	$ 20,002
Long-term investments, at fair value	4,095	4,160
Total	44,046	24,162
U.S. Treasury Bills [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities	39,951	19,998
Mutual Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities		4
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities	39,951	20,002
Long-term investments, at fair value	0	0
Total	39,951	20,002
Fair Value, Inputs, Level 1 [Member] | U.S. Treasury Bills [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities	39,951	19,998
Fair Value, Inputs, Level 1 [Member] | Mutual Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities		4
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities	0	0
Long-term investments, at fair value	0	0
Total	0	0
Fair Value, Inputs, Level 2 [Member] | U.S. Treasury Bills [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities	0	0
Fair Value, Inputs, Level 2 [Member] | Mutual Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities		0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities	0	0
Long-term investments, at fair value	4,095	4,160
Total	4,095	4,160
Fair Value, Inputs, Level 3 [Member] | U.S. Treasury Bills [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities	$ 0	$ 0

Changes in Fair Value of Financ

Changes in Fair Value of Financial Instruments (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2014	$ 4,160
Change in fair value of investment	(65)
Balance at September 30, 2015	4,095
CB Pharma Acquisitions Corp [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2014	3,910
Change in fair value of investment	(65)
Balance at September 30, 2015	3,845
Short-term Investments [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2014	0
Change in fair value of investment	0
Balance at September 30, 2015	0
Other Long-term Investments [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2014	250
Change in fair value of investment	0
Balance at September 30, 2015	$ 250

Investments at Fair Value - Add

Investments at Fair Value - Additional Information (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2015	Oct. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Method Investments	$ 250,000		$ 200,000
Trading Securities	$ 39,951,000		20,002,000
Fair Value Assumptions, Weighted Average Volatility Rate	25.40%
Share Price	$ 9.49
Investments in and Advances to Affiliates, at Fair Value, Period Increase (Decrease)	$ 1,400,000
Investment Owned, at Fair Value	3,800,000
Working Capital	500,000
Working Capital Committed	100,000
Additional Paid In Capital	$ 231,684,000	$ 50,000	212,205,000
Business Acquisition, Percentage of Voting Interests Acquired	31.69%
Redeemable warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Share Price	$ 0.27
Non Redeemable warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Share Price	0.30
Ghaidarov Model [Member] | Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Share Price	$ 0.84
Binomial Lattice Model [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Risk Free Interest Rate	1.37%
Fair Value Assumptions, Expected Volatility Rate	25.40%
Fair Value Assumptions, Exercise Price	$ 11.50
Binomial Lattice Model [Member] | Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Share Price	$ 0.95
US Treasury Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities	$ 40,000,000		$ 20,000,000
Common Stock Subject to Mandatory Redemption [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Net Assets	$ 42,600,000
Private Units [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Share Price	$ 3
Insider Shares [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Share Price	8.99
Business Acquisition, Share Price	$ 2.84

Stockholders' Equity - Employee

Stockholders' Equity - Employee Stock Purchase Programs (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 8,501	$ 1,484	$ 11,896	$ 4,082
Fortress Companies [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2,966	0	3,359	0
Employee Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	3,296	1,460	6,284	4,035
Executive Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2,229	0	2,229	0
Non-Employee Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 10	$ 24	$ 24	$ 47

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares,Outstanding at December 31, 2014	2,164,365
Number of Shares, Options granted	0
Number of Shares, Options exercised	(100,000)
Number of Shares,Options cancelled	(285,000)
Number of Shares, Outstanding at September 30, 2015	1,779,365	2,164,365
Total Weighted Average Intrinsic Value, Options cancelled	1,632,698
Weighted Average Exercise Price,Outstanding at December 31, 2014	$ 4.69
Weighted Average Exercise Price, Options granted	0
Weighted Average Exercise Price, Options exercised	2.15
Weighted Average Exercise Price,Options cancelled	7.57
Weighted Average Exercise Price, Outstanding at September 30, 2015	4.37	$ 4.69
Weighted Average Exercise Price, Options vested and expected to vest	$ 4.40
Total Weighted Average Intrinsic Value, Outstanding at December 31, 2014	$ 0
Total Weighted Average Intrinsic Value, Options granted	0
Total Weighted Average Intrinsic Value, Options exercised	45
Total Weighted Average Intrinsic Value, Options cancelled	1,417
Total Weighted Average Intrinsic Value, Outstanding at September 30, 2015	0	$ 0
Total Weighted Average Intrinsic Value, Options vested and exercisable	$ 0
Weighted Average Remaining Contractual Life, Outstanding	6 years 6 months 25 days	7 years 4 months 17 days
Weighted Average Remaining Contractual Life, Options vested and exercisable	6 years 5 months 12 days

Stockholders' Equity - Restrict

Stockholders' Equity - Restricted Stock Activity (Detail)	9 Months Ended
	Sep. 30, 2015$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock granted	1,950,000
Restricted stock vested	(250,000)
Unvested balance at September 30, 2015	1,700,000
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested balance at December 31, 2014	8,287,384
Restricted stock granted	200,000
Restricted stock vested	(816,449)
Restricted stock units granted	1,412,000
Restricted stock units vested	(335,000)
Unvested balance at September 30, 2015	8,747,935
Unvested balance at December 31, 2014 | $ / shares	$ 2.33
Restricted stock granted (Fair Value) | $ / shares	3.04
Restricted stock vested (Fair Value) | $ / shares	2.69
Restricted stock units granted (Fair Value) | $ / shares	3.58
Restricted stock units vested (Fair Value) | $ / shares	3.56
Unvested balance at September 30, 2015 | $ / shares	$ 2.53

Stockholders' Equity - Warrants

Stockholders' Equity - Warrants (Detail)	9 Months Ended
	Sep. 30, 2015USD ($)$ / sharesshares
Mustang [Member]
Class of Warrant or Right, Outstanding | shares	1,000,000
Fair Value Assumptions, Risk Free Interest Rate	2.36%
Fair Value Assumptions, Expected Volatility Rate	106.11%
Fair Value Assumptions, Expected Term	20 years
Fair Value Assumptions, Exercise Price | $ / shares	$ 0.147
Warrants and Rights Outstanding	$ 135
Checkpoint [Member]
Class of Warrant or Right, Outstanding | shares	1,000,000
Fair Value Assumptions, Risk Free Interest Rate	2.36%
Fair Value Assumptions, Expected Volatility Rate	106.11%
Fair Value Assumptions, Expected Term	20 years
Fair Value Assumptions, Exercise Price | $ / shares	$ 0.129
Warrants and Rights Outstanding	$ 118
Avenue [Member]
Class of Warrant or Right, Outstanding | shares	1,000,000
Fair Value Assumptions, Risk Free Interest Rate	2.36%
Fair Value Assumptions, Expected Volatility Rate	106.11%
Fair Value Assumptions, Expected Term	20 years
Fair Value Assumptions, Exercise Price | $ / shares	$ 0.146
Warrants and Rights Outstanding	$ 134
CNDO SO [Member]
Class of Warrant or Right, Outstanding | shares	1,000,000
Fair Value Assumptions, Risk Free Interest Rate	2.36%
Fair Value Assumptions, Expected Volatility Rate	106.11%
Fair Value Assumptions, Expected Term	20 years
Fair Value Assumptions, Exercise Price | $ / shares	$ 1.190
Warrants and Rights Outstanding	$ 1,092
Helocyte [Member]
Class of Warrant or Right, Outstanding | shares	1,000,000
Fair Value Assumptions, Risk Free Interest Rate	2.36%
Fair Value Assumptions, Expected Volatility Rate	106.11%
Fair Value Assumptions, Expected Term	20 years
Fair Value Assumptions, Exercise Price | $ / shares	$ 0.097
Warrants and Rights Outstanding	$ 89
JMC [Member]
Class of Warrant or Right, Outstanding | shares	1,000,000
Fair Value Assumptions, Risk Free Interest Rate	2.36%
Fair Value Assumptions, Expected Volatility Rate	106.11%
Fair Value Assumptions, Expected Term	20 years
Fair Value Assumptions, Exercise Price | $ / shares	$ 0.650
Warrants and Rights Outstanding	$ 596
Escala [Member]
Class of Warrant or Right, Outstanding | shares	1,000,000
Fair Value Assumptions, Risk Free Interest Rate	2.36%
Fair Value Assumptions, Expected Volatility Rate	106.11%
Fair Value Assumptions, Expected Term	20 years
Fair Value Assumptions, Exercise Price | $ / shares	$ 0.071
Warrants and Rights Outstanding	$ 65

Stockholders' Equity - Restri55

Stockholders' Equity - Restricted Stock Unit (Detail)	9 Months Ended
	Sep. 30, 2015$ / sharesshares
Restricted stock granted	1,950,000
Vested	250,000
Unvested	1,700,000
Sales [Member]
Restricted stock granted	450,000
Vesting Term	4 years
Vested	0
Unvested	450,000
Fair value per Share | $ / shares	$ 0.650
President [Member]
Restricted stock granted	1,500,000	[1]
Vesting Term	4 years	[1]
Vested	250,000	[1]
Unvested	1,250,000	[1]
Fair value per Share | $ / shares	$ 0.650	[1]
[1]	Vesting is performance based.

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	Sep. 08, 2015	Jul. 15, 2015	Jul. 28, 2015	Jun. 30, 2013	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense related to all unvested stock option					$ 100,000				$ 100,000
Stock-based compensation weighted-average vesting period									1 year 11 months 12 days
Employee Stock Purchase Plan to eligible employees, Number of shares purchased by employees					77,875				77,875
Employee Stock Purchase Plan to eligible employees, Number of shares available for future sales					122,125				122,125
Employee Stock Purchase Plan to eligible employees, compensation expense recognized					$ 12,600			$ 4,200	$ 27,500	$ 19,900
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options					$ 3,200,000				$ 3,200,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition									1 year 11 months 12 days
Share Price					$ 9.49				$ 9.49
Research And Development Expense					$ 9,073,000			1,609,000	$ 13,172,000	8,473,000
General And Administrative Expense					7,129,000			2,737,000	14,376,000	7,218,000
Stock Issued During Period, Value, Issued for Services									1,000	4,000
Employee Benefits And Share Based Compensation					8,501,000			1,484,000	$ 11,896,000	4,082,000
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross									0
Acquisition Of License [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense					600,000				$ 900,000
Consultants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense									$ 4,300,000
Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense					2,200,000
Stock Issued During Period, Shares, Issued for Services									1
Mr. George Avgerinos [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		50.00%
Stock Issued During Period, Value, Issued for Services					1,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost		$ 3,700,000
Mr. Avgerinos [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross				200,000
David Barrett [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Issued During Period, Value, Issued for Services					400,000
Dov Klien [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		4 years
Senior Vise President [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Research And Development Expense					3,700,000
Allocated Share-based Compensation Expense					302,015,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		10.00%
Former Board Of Director [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense					500,000
Dr. Rosenwald [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		500,000
Mr. Weiss [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		500,000
Mustang [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Benefits And Share Based Compensation									$ 147,000
Avenue Therapeutics, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted Market Value Percentage of Invested Capital						44.80%
Weighted Average Cost Percentage of Capital						30.00%
Shares Issued, Price Per Share						$ 0.146
Stock Issued During Period, Value, Issued for Services					$ 14,700				37,600
Employee Benefits And Share Based Compensation									37,600
Avenue Therapeutics, Inc. [Member] | Consultants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Issued During Period, Shares, Issued for Services					150,000	150,000
Stock Issued During Period, Value, Issued for Services					$ 15,000				37,600
Avenue Therapeutics, Inc. [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Issued During Period, Shares, Issued for Services						1,000,000
Avenue Therapeutics, Inc. [Member] | Share-based Compensation Award, Tranche One [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						50.00%
Avenue Therapeutics, Inc. [Member] | Share-based Compensation Award, Tranche Two [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						12.50%
Avenue Therapeutics, Inc. [Member] | Share-based Compensation Award, Tranche Three [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						50.00%
Coronado SO Co. [Member] | Acquisition Of License [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Benefits And Share Based Compensation									178,500
Mustang Bio, Inc [Member] | Acquisition Of License [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Benefits And Share Based Compensation									147
Journey Medical Corporation [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense related to all unvested stock option					500,000				$ 500,000
Stock-based compensation weighted-average vesting period									0 years
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition									0 years
Share Price			$ 0.65
General And Administrative Expense					279,000				$ 279,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period									1 year 25 days
Weighted Market Value Percentage of Invested Capital			44.50%
Weighted Average Cost Percentage of Capital			30.00%
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross			1,950,000
Journey Medical Corporation [Member] | Acquisition Of License [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Benefits And Share Based Compensation									$ 279,500
Checkpoint Therapeutics, Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term							5 years
Share Price							$ 4.39
Research And Development Expense					$ 2,100,000
Allocated Share-based Compensation Expense									1,500,000
Fair Value Assumptions, Expected Volatility Rate							83.00%
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total							$ 1,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage							25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period							48 months
Weighted Market Value Percentage of Invested Capital		44.80%
Weighted Average Cost Percentage of Capital		30.00%
Employee Benefits And Share Based Compensation									$ 2,100,000
Fair Value Assumptions, Risk Free Interest Rate							1.54%		1.54%
Debt Issuance Cost									$ 12,600,000
Debt Instrument, Offering Date	Nov. 30, 2015
Checkpoint Therapeutics, Inc [Member] | Acquisition Of License [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Benefits And Share Based Compensation									$ 600,000
Warrant [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Class of Warrant or Right, Outstanding					685,061				685,061		685,061
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 6.65
Research and Development Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense					$ 4,300,000			300,000	$ 5,200,000	900,000
General and Administrative Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense					$ 4,200,000			$ 1,200,000	$ 6,700,000	$ 3,100,000
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation weighted-average vesting period									1 year 4 months 24 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition									1 year 4 months 24 days
Deferred Compensation Arrangement with Individual, Shares Issued									290,000
Restricted Stock Units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross		50,000
Restricted Stock Units (RSUs) [Member] | Mr. George Avgerinos [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross		1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares					300,000
Restricted Stock Units (RSUs) [Member] | David Barrett [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross		133,000
Restricted Stock Units (RSUs) [Member] | Dov Klien [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense related to all unvested stock option					$ 10,100,000				$ 10,100,000
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross		40,000
New Award [Member] | Mr. George Avgerinos [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost		$ 3,300,000
Old Award [Member] | Mr. George Avgerinos [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost		$ 400,000

Related Party Note - Additional

Related Party Note - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 17, 2015	Mar. 17, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Related Party Transaction [Line Items]
Costs and Expenses, Related Party			$ 66,000	$ 40,000	$ 153,700	$ 79,000
Agreement Description Terms		issue annually to the Company, on the anniversary date of the Founders Agreement, shares of Checkpoint common stock equal to 2.25% of the fully-diluted outstanding equity of Checkpoint at the time of issuance; (ii) pay an equity fee in shares of Checkpoint common stock, payable within five (5) business days of the closing of any equity or debt financing for Checkpoint or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when the Company no longer has majority voting control in Checkpoints voting equity, equal to 2.25% of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to 4.5% of its annual net sales, payable on an annual basis, within 90 days of the end of each calendar year. In the event of a change in control (as defined in the Founders Agreement), the Company will pay a one-time change in control fee equal to five times (5x) the product of (i) monthly net sales for the 12 months immediately preceding the change in control and (ii) 4.5%
Payment of Fund							$ 0
Working Capital			500,000		500,000
Cb Pharma Acquisition Corp [Member]
Related Party Transaction [Line Items]
Working Capital			500,000		500,000		$ 100,000
TG Therapeutics, Inc [Member]
Related Party Transaction [Line Items]
Increase (Decrease) in Accounts Receivable				$ 0	71,800	$ 0
Accounts Receivable, Net, Total			$ 69,300		69,300
Collaboration Agreement with TGTX [Member]
Related Party Transaction [Line Items]
Underwriting Commission Incurred	$ 25,000
Payments for Fees					500,000
Collaboration Agreement with TGTX [Member] | TG Therapeutics, Inc [Member]
Related Party Transaction [Line Items]
Payments for Fees					500,000
Management Services Agreement [Member]
Related Party Transaction [Line Items]
Debt Issuance Cost					$ 2,800,000
Agreement Service Period		5 years

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($)	1 Months Ended
	Oct. 31, 2015	Sep. 30, 2015
Subsequent Event [Line Items]
Working Capital		$ 500,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Debt Issuance Cost	$ 12,600,000
Allocated Share-based Compensation Expense	1,300,000
Subsequent Event [Member] | Cb Pharma Acquisition Corp [Member]
Subsequent Event [Line Items]
Working Capital	$ 50,000